吉非替尼治疗非小细胞肺癌的研究进展

被引：18

作者：

张彬 ^{[1
,2
]}

李明春 ^{[1
]}

机构：

[1] 解放军第医院药剂科

[2] 青岛大学药学院

来源：

中国药房 | 2014年 / 25卷 / 06期

关键词：

吉非替尼; 表皮生长因子; 酪氨酸激酶; 非小细胞肺癌;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

目的:总结吉非替尼治疗非小细胞肺癌的研究进展,为该药的临床应用提供参考。方法:通过检索PubMed中近10年来关于吉非替尼的文献,对吉非替尼的作用机制、药理特点以及临床应用等方面进行归纳分析。结果和结论:吉非替尼治疗非小细胞肺癌的疗效确切但易产生不良反应、获得性耐药性;吉非替尼基因组学研究和临床上联合用药以及个体化用药是未来的研究热点。

引用

页码：550 / 554

页数：5

共 14 条

[1]

Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report [J].

Xue, Xinying ;

Xue, Qingliang ;

Liu, Yuxia ;

Pan, Lei ;

Wang, Kaifei ;

Zhang, Lina ;

Wang, Na ;

Yang, Bing ;

Wang, Jianxin .

ONCOLOGY LETTERS, 2013, 5 (05) :1599-1600

[2]

Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study [J].

Tateishi, Kazunari ;

Ichiyama, Takashi ;

Hirai, Kazuya ;

Agatsuma, Toshihiko ;

Koyama, Shigeru ;

Hachiya, Tsutomu ;

Morozumi, Nobutoshi ;

Shiina, Takayuki ;

Koizumi, Tomonobu .

MEDICAL ONCOLOGY, 2013, 30 (01)

[3]

Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients [J].

Rong Biaoxue ;

Yang Shuanying ;

Li Wei ;

Zhang Wei ;

Ming Zongjuan .

CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) :1699-1708

[4]

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications [J].

Yasuda, Hiroyuki ;

Kobayashi, Susumu ;

Costa, Daniel B. .

LANCET ONCOLOGY, 2012, 13 (01) :E23-E31

[5]

Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China [J].

Wu, Yi-Long ;

Chu, Da-Tong ;

Han, Baohui ;

Liu, Xuyi ;

Zhang, Li ;

Zhou, Caicum ;

Liao, Meilin ;

Mok, Tony ;

Jiang, Haiyi ;

Duffield, Emma ;

Fukuoka, Masahiro .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (03) :232-243

[6]

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer [J].

Nakamura, Yoichi ;

Sano, Kazumi ;

Soda, Hiroshi ;

Takatani, Hiroshi ;

Fukuda, Minoru ;

Nagashima, Seiji ;

Hayashi, Tomayoshi ;

Oka, Mikio ;

Tsukamoto, Kazuhiro ;

Kohno, Shigeru .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (09) :1404-1409

[7]

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].

Ferlay, Jacques ;

Shin, Hai-Rim ;

Bray, Freddie ;

Forman, David ;

Mathers, Colin ;

Parkin, Donald Maxwell .

INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917

[8]

Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines [J].

Galetti, Maricla ;

Alfieri, Roberta R. ;

Cavazzoni, Andrea ;

La Monica, Silvia ;

Bonelli, Mara ;

Fumarola, Claudia ;

Mozzoni, Paola ;

De Palma, Giuseppe ;

Andreoli, Roberta ;

Mutti, Antonio ;

Mor, Marco ;

Tiseo, Marcello ;

Ardizzoni, Andrea ;

Petronini, Pier Giorgio .

BIOCHEMICAL PHARMACOLOGY, 2010, 80 (02) :179-187

[9]

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial [J].

Kim, Edward S. ;

Hirsh, Vera ;

Mok, Tony ;

Socinski, Mark A. ;

Gervais, Radj ;

Wu, Yi-Long ;

Li, Long-Yun ;

Watkins, Claire L. ;

Sellers, Mark V. ;

Lowe, Elizabeth S. ;

Sun, Yan ;

Liao, Mei-Lin ;

Osterlind, Kell ;

Reck, Martin ;

Armour, Alison A. ;

Shepherd, Frances A. ;

Lippman, Scott M. ;

Douillard, Jean-Yves .

LANCET, 2008, 372 (9652) :1809-1818

[10]

The role of the EGFR signaling in tumor microenvironment.[J].AntonellaDe Luca;AdeleCarotenuto;AnnamariaRachiglio;MariannaGallo;Monica R.Maiello;DonatellaAldinucci;AntonioPinto;NicolaNormanno.J. Cell. Physiol..2007, 3

← 1 2 →